Forbion - Home

At Forbion Capital Partners we invest in Life Sciences and Biomedical Technology companies developing world-class drugs and technologies, with a clear focus on product development.

Learn more »

'For Biotech and Beyond'

01.02.2012 Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC) » 01.02.2012 EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-‐Derived Exosome Diagnostics » 09.01.2012 AM-Pharma Announces Appointment of Russell Greig as Chairman »

Pictures